Chronische Lymphatische Leukämie (CLL)
CLL-Register
Register der Deutschen CLL Studiengruppe (DCLLSG): Langzeit Nachbeobachtung von Patienten mit CLL, B-PLL, T-PLL, SLL, T/ NK-LGL, HCL und Richter Transformation
CLL16
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZUMAB AND VENETOCLAX (GVE) IN PREVIOUSLY UNTREATED PATIENTS WITH HIGH RISK (17P-DELETION, TP53- MUTATION OR COMPLEX KARYOTYPE) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
CLL18
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes